Jul 31, 2023 / 12:00PM GMT
Operator
Good morning, and welcome to ImmunoGen's Second Quarter 2023 Financial and Operating Results Conference Call. Today's conference is being recorded. At this time, I'd like to turn the call over to Anabel Chan, Head of Investor Relations. Please go ahead.
Anabel Chan - ImmunoGen, Inc. - Head of IR
Good morning, and thank you for joining today's call. Earlier today, we issued a press release that includes a summary of our recent operating progress and second quarter financial results. This press release, a recording of this call and an updated corporate deck can be found under the Investors and Media section of our website at immunogen.com.
With me today are Mark Enyedy, our President and CEO; Isabel Kalofonos, our Chief Commercial Officer; Anna Berkenblit, our Chief Medical Officer; and Renee Lentini, our Interim CFO. Michael Vasconcelles, our EVP of Research, Development and Medical Affairs, will also join us for Q&A.
During today's call, we will review recent progress for the business, our financial results and highlight upcoming
Q2 2023 ImmunoGen Inc Earnings Call Transcript
Jul 31, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers